Enronit
Enrofloxacin, colistin
Enrofloxacin, colistin
Enronit
Complex drug with synergistic effect of enrofloxacin and colistin that is highly effective against colibacillosis to which resistance is slowly developing
- More effective than enrofloxacin-based monodrugs with comparable cost of treatment
- Long-time use of the drug due to low development of resistance of microorganisms compared to enrofloxacin-based monodrugs
- Highly effective against colibacillosis
- Synergistic effect of the drug components
Composition
Pharmacological properties
Indications
Dosage and method of administration
Restrictions
1 ml Enronit
enrofloxacin 50 mg
colistin 500 000 IU
Please note: The information given on this page is for an informative purpose only. Product characteristics, packaging, label design and overall appearance may vary in different regions. Contact our representatives for more information.
Pharmacological properties
The synergistic combination of enrofloxacin and colistin sulfate provides a broad-spectrum antimicrobial activity against gram-positive and gram-negative microbes.
Enrofloxacin inhibits the activity of gyrase, an enzyme that affects the replication of DNA spiral in the nucleus of the bacterial cell, thus disrupting the protein synthesis and suppressing the growth and development of gram-positive and gram-negative bacteria including:
- Escherichia coli
- Haemophilus spp.
- Pasteurella spp.
- Salmonella spp.
- Staphylococcus spp.
- Streptococcus spp.
- Clostridium perfringens
- Bordetella spp.
- Campylobacter spp.
- Corynebacterium pyogenes
- Pseudomonas aeruginosa
- Mycoplasma spp.
- Enterobacter spp.
- Proteus mirabilis
- Proteus vulgaris
- Klebsiella spp.
- Erysipelothrix spp.
- Actinobacillus spp.
- Fusobacterium spp.
- Bacteroides spp.
Please note: The information given on this page is for an informative purpose only. Product characteristics, packaging, label design and overall appearance may vary in different regions. Contact our representatives for more information.
Indications
Enronit is prescribed to treat following diseases: for calves, and lambs – colibacillosis, salmonellosis, pasteurellosis, respiratory, and other diseases caused by enrofloxacin- and colistin sulfate-sensitive microbes; for piglets – colibacillosis, salmonellosis, pasteurellosis, respiratory, and other diseases caused by enrofloxacin- and colistin sulfate-sensitive microbes; for adult pigs – atrophic rhinitis, enzootic pneumonia, and MMA-syndrome.
Please note: The information given on this page is for an informative purpose only. Product characteristics, packaging, label design and overall appearance may vary in different regions. Contact our representatives for more information.
Dosage and method of administration
| Animal | Method of administration | Dosage | Treatment period |
|---|---|---|---|
| Calves and lambs | Subcutaneously | 0.5 ml /10 kg of animal body weight, once | 3-5 days |
| Piglets | Intramuscularly | ||
| Sows with MMA-syndrome | 1-2 days |
As a pain reaction may occur, avoid administering more than 5 ml to calves and pigs, and more than 2.5 ml of the drug to lambs and piglets in one injection site.
Please note: The information given on this page is for an informative purpose only. Product characteristics, packaging, label design and overall appearance may vary in different regions. Contact our representatives for more information.
Restrictions
Contraindications and special instructions:
Avoid using Enronit simutaneously with chloramphenicol, macrolide antibiotics group and tetracycline, theophylline, and nonsteroidal anti-inflammatory agents.
Withdrawal period:
meat - 21 days
Please note: The information given on this page is for an informative purpose only. Product characteristics, packaging, label design and overall appearance may vary in different regions. Contact our representatives for more information.
Similar products
NEW
NEW
